About Us

Cardiome Overview

Patient Centered Research

Cardiome is a research-based biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the quality of life and health of patients.  We strive to find innovative medicines that provide value to patients, physicians and healthcare systems.  

We have one marketed product, BrinavessTM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.  Our lead clinical programs are also focused on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart.  We have several pre-clinical projects directed at various therapeutic indications for which there is a high unmet medical need. 

Our Research Approach

We are becoming a fully integrated biopharmaceutical company, with demonstrable expertise in discovery research to clinical development.  We have particular expertise in ion-channel modulation and in diseases associated with ion-channel dysfunction, which can range from cardiovascular to cancer to neurological and CNS disorders.  Our research approach led to the discovery and development of vernakalant, which has been approved as a “first-in-class” frequency dependent ion-channel modulator.

Community Involvement

At Cardiome, we are committed to giving back to our local community.  Our employees are actively involved in a spectrum of initiatives and programs, ranging from community partnerships with charitable organizations to employee volunteerism in programs such as Inspiring Science.  For more information, visit our Corporate Responsibility section.  

Investor Information

Cardiome is traded on the NASDAQ Global Market (CRME) and the Toronto Stock Exchange (COM).  For more information visit our Investors section.